Beyond exon 2--the developing story of RAS mutations in colorectal cancer. Berlin J (2013) N Engl J Med 369: 1059-60 The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B (2012) Nature 486: 537-40 Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Hecht JR, Mitchell E, Neubauer MA, Burris HA, Swanson P, Lopez T, Buchanan G, Reiner M, Gansert J, Berlin J (2010) Clin Cancer Res 16: 2205-13 Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. Rosen LS, Puzanov I, Friberg G, Chan E, Hwang YC, Deng H, Gilbert J, Mahalingam D, McCaffery I, Michael SA, Mita AC, Mita MM, Mulay M, Shubhakar P, Zhu M, Sarantopoulos J (2012) Clin Cancer Res 18: 3414-27 Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051). Lockhart AC, Reed CE, Decker PA, Meyers BF, Ferguson MK, Oeltjen AR, Putnam JB, Cassivi SD, Montero AJ, Schefter TE, American College of Surgeons Oncology Group (2014) Ann Oncol 25: 1039-44 Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ (2007) Cancer 110: 980-8 The epidermal growth factor receptor as a target for colorectal cancer therapy. Lockhart AC, Lockhart C, Berlin JD (2005) Semin Oncol 32: 52-60 Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosi I, Radinsky R, Amado RG (2008) Clin Colorectal Cancer 7: 184-90 Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. Berlin J, Posey J, Tchekmedyian S, Hu E, Chan D, Malik I, Yang L, Amado RG, Hecht JR (2007) Clin Colorectal Cancer 6: 427-32
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.